Acalabrutinib with bendamustine and rituximab is now an FDA-approved treatment for patients with previously untreated mantle ...

Cambridge: AstraZeneca has announced that the Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) in ...

Sergio A. Giralt, MD, discusses how rituximab plays a key role in treating chronic graft-vs-host disease. It is often used in combination with ibrutinib to enhance therapeutic outcomes. He reviews the ...

Samsung Bioepis' Q1 2025 report shows oncology, ophthalmology, and pegfilgrastim biosimilars have gained significant market share, while immunology, filgrastim, epoetin alfa, and insulin glargine ...

Celltrion’s biosimilar marketing strategy in Europe has got seriously confusing after the firm asked to market its rituximab near-copy under four different brands. Its biosimilar of Roche’s ...

The FDA approved acalabrutinib in combination with bendamustine and rituximab for adults with previously untreated mantle ...

Dr Reddy's Laboratories Ltd (RDY) reports a robust 16% YoY revenue growth, driven by strategic product launches and market ...

An investigational induced pluripotent stem cell-derived CAR natural killer cell therapy was well tolerated both as ...

A small, but positive, randomized double-blind trial of baricitinib for PMR is the first in patients with the condition to ...

A temporary freeze on meetings on the National Institutes of Health could lead to delays in disbursing research grants and in ...